Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Study Phase : Approved
Recipient : Adalvo
Deal Size : Not Applicable
Deal Type : Not Applicable
Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe
Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Brand Name : Vesomni-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2023
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Highest Development Status : Approved
Recipient : Adalvo
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?